Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × gilteritinib × Clear all

Phase

Phase 1 14 Phase 1/2 13 Phase 2 11 Phase 3 9 Phase NA 2 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 97 Gemcitabine 64 Paclitaxel 61 Carboplatin 60 Docetaxel 59 Capecitabine 59 Fluorouracil 58 Oxaliplatin 56 Cyclophosphamide 54 Radiotherapy 50 Drug Therapy 46 Bevacizumab 37 pembrolizumab 36 Leucovorin 32 Magnetic Resonance Spectroscopy 31 Doxorubicin 31 Dexamethasone 31 Cytarabine 27 Etoposide 26 Pemetrexed 25 Nivolumab 24 Methotrexate 24 Radiation 20 Vincristine 18 apatinib 17 Rituximab 17 Prednisone 17 Letrozole 17 venetoclax 16 Trastuzumab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07425808 2026-02-23

FIT-AML

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡